Edgestream Partners, L.P.

Position in EXEL — Exelixis, Inc.

CIK 1535061 Princeton, NJ

Position in EXEL

as of Mar 31, 2026 · filed May 18, 2026 Compact

Position Value

$7,482,374

+$1,166,515 QoQ

Shares Held

174,455

+21.1% QoQ

Ownership

0.069%

of shares outstanding

% of Portfolio

0.26%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2023

11 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Edgestream Partners, L.P. holds $88,282,973 across 25 Biotechnology names. EXEL ranks #2 (8.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	INCY	Incyte Corp	157,472	$14,821,264
2	EXEL	Exelixis, Inc. This page	174,455	$7,482,374
3	RVMD	Revolution Medicines, Inc.	69,262	$6,735,729
4	ARWR	Arrowhead Pharmaceuticals, Inc.	91,997	$5,768,211
5	TGTX	Tg Therapeutics, Inc.	168,351	$5,592,620
6	IONS	Ionis Pharmaceuticals Inc	68,369	$5,133,828
7	AGIO	Agios Pharmaceuticals, Inc.	143,731	$4,862,419
8	ACAD	Acadia Pharmaceuticals Inc	191,328	$4,258,961

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$7,482,374	174,455	+21.1%	Shares	Sole	2026-05-18
2025-12-31	$6,315,859	144,099	+350.4%	Shares	Sole	2026-02-13
2025-09-30	$1,321,310	31,993	-26.0%	Shares	Sole	2025-11-12
2025-03-31	$1,596,310	43,237	-60.8%	Shares	Sole	2025-05-02
2024-12-31	$3,672,756	110,293	+50.7%	Shares	Sole	2025-02-07
2024-09-30	$1,899,747	73,208	-36.2%	Shares	Sole	2024-11-14
2024-06-30	$2,579,218	114,785	+128.6%	Shares	Sole	2024-08-09
2024-03-31	$1,191,578	50,214	-61.6%	Shares	Sole	2024-05-10
2023-12-31	$3,138,755	130,836	+153.7%	Shares	Sole	2024-02-14
2023-09-30	$1,126,891	51,574	-53.5%	Shares	Sole	2023-11-15
2023-06-30	$2,117,598	110,811	—	Shares	Sole	2023-08-10
No filing history on record for this holder in this stock.